DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to demonstrate compliance with a continued listing requirement of The Nasdaq Global Select Market. As previously reported in a Current Report on Form 6-K filed November 29, 2023, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq ...

-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025- -Entered into MedScience distribution agreement in UK effective as of August 1, 2024 which encompasses clinical chemistry, infectious disease, and autoimmune products- DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) ...

-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025- -Entered into MedScience distribution agreement in UK effective as of August 1, 2024 which encompasses clinical chemistry, infectious disease, and autoimmune products- DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) ...

Louise Tallon responded, "I'm excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of a next generation CGM device." This release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, fin ...

Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next genera ...

This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Forward-Looking Statements Gary Keating, Ph.D. Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: investorr ...

This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Trinity Biotech President and Chief Executive Officer, Mr John Gillard stated "We believe our CGM solution an ...

About Trinity Biotech Management plans to host meetings with key stakeholders and potential partners as it works to advance the next generation of its recently acquired continuous glucose monitoring (CGM) biosensor technology. Interested parties are invited to reach out for more information by emailing Biosensors@trinitybiotech.com. To learn more about Trinity's CGM, please visit https://cgm.trinitybiotech.com LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Co ...

DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. About Trinity Biotech LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trini ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bio ...